



A nonprofit independent licensee of the Blue Cross Blue Shield Association

Medication Assurance Program

If you are enrolled in a commercial health benefit plan provided by or administered by Excellus BlueCross BlueShield where the Medication Assurance Program benefit applies:

The following drugs were preliminarily approved through the accelerated approval pathway by the U.S. Food and Drug Association (FDA). At this time, these drugs have unconfirmed clinical benefit and will not be covered under prescription drug benefits or medical benefits. Drug manufacturers of the drugs listed below are required to conduct clinical studies to prove clinical benefit in order to achieve traditional/final FDA approval. These drugs will continue to be monitored and remain uncovered until clinical benefits are proven and confirmed by criteria set forth by the FDA.

- ADSTILADRIN*
- ADUHELM*
- ALIQOPA*
- AMONDYS 45*
- ARIKAYCE
- BALVERSA
- BELEODAQ*
- COLUMVI
- DANYELZA*
- ELAHERE*
- ELEVIDYS*
- ELREXFIO*
- EPKINLY*
- EXKIVITY
- EXONDYS 51*
- FILSPARI
- FOLOTYN*
- GALAFOLD
- JAYPIRCA
- LUNSUMIO*
- LYTGobi
- MONJUVI*
- NORTHERA
- OCALIVA
- OXBRYTA
- PRALATREXATE*
- QALSODY*
- RYBREVANT*
- SIRTURO
- SKYSONA*
- TALVEY*
- TARPEYO
- TAZVERIK
- TECVAYLI*
- TEPMETKO
- TIVDAK*
- VILTEPSO*
- VONJO
- VOXZOGO
- VYONDYS 53*
- ZEPZELCA*
- ZYNLONTA*
- ZYNYZ*

If you have questions regarding your drug coverage, please contact customer care at the number on the back of your card.

*Medical benefit drug

Updated 9/12/2023